-
公开(公告)号:ES2273278T3
公开(公告)日:2007-05-01
申请号:ES04742999
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
Inventor: OWEN DAVID ALAN , WATSON ROBERT JOHN , ALLEN DANIEL REES , SHARPE ANDREW , DYKE HAZEL JOAN
IPC: C07D211/96 , A61K31/451 , A61P37/00
Abstract: Un compuesto de fórmula (1): en la que: Ci es un grupo arilo o heteroarilo; m es cero o el número entero 1, 2 ó 3; n es cero o el número entero 1, 2 ó 3; en el que la suma de m y n es cero o el número entero 1, 2 ó 3; R1 es un grupo seleccionado de alquilo C1-6, arilo, heteroarilo, heterocicloal- quilo, cicloalquilo C3-6, -alquil C1-6-arilo, -alquil C1-6-heteroarilo, - alquil C1-6-heteroci- cloalquilo o -alquil C1-6-cicloalquilo C3-6, en el que cada grupo arilo o heteroarilo, pre- sente como grupo R1 o como parte del mismo, puede estar sustituido opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo R7, en el que cada R7 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, Cl, Br, alquilo C1-6, haloal- quilo C1-6, alcoxi C1-6, haloalcoxi C1-6, -CN, -CO2R7a, -CON(R7a)2 o -COR7a; y en el que cada grupo alquilo, heterocicloalquilo o cicloalquilo, presente como grupo R1 o como parte del mismo, puede estar sustituido opcionalmente con 1, 2 ó 3 sustituyentes se- leccionados del grupo R8, en el que cada R8 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, =O, =NOR10, -CO2R8a, -CON(R8a)2 o -COR8a; R7a, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno, o un grupo alquilo C1-6 o haloalquilo C1-6; R8a, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno, o un grupo alquilo C1-6 o haloalquilo C1-6; R10 es un átomo de hidrógeno o un grupo alquilo C1-3; R2 es un átomo de hidrógeno o un grupo alquilo C1-3; o R1 y R2 junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo C3-6 o heterocicloalquilo sustituido opcionalmente con 1, 2 ó 3 sustituyentes seleccionados del grupo R9, en el que cada R9 puede ser igual o diferente, y es un átomo o grupo seleccionado de F, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, =O, =NOR10, -CO2R8a, -CON(R8a)2 o -COR8a; R3 es un átomo o grupo seleccionado de F, Cl, Br, alquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3 o -CN; R4 es un átomo de hidrógeno, F, Cl o Br o un grupo alquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3, -CN, -SO2R5, -SO2N(R6)2, -CON(R6)2, -N(R6)2, -NHSO2R5 o - NHCOR5; R5 es un grupo alquilo C1-3; R6, que pueden ser iguales o diferentes, son cada uno un átomo de hidrógeno o un grupo alquilo C1-3; y Ra y Rb, que pueden ser iguales o diferentes, son cada uno un átomo o grupo seleccionado de hidrógeno o alquilo C1-3, o Ra y Rb pueden estar unidos para formar un grupo cicloalquilo C3-6 o heterocicloalquilo como se definió para R1 y R2; y sus sales, solvatos, hidratos, tautómeros, isómeros o N-óxidos.
-
公开(公告)号:ZA200509717B
公开(公告)日:2007-03-28
申请号:ZA200509717
申请日:2004-06-18
Applicant: CELLTECH R&D LTD
IPC: A61K20090101 , A61P20090101 , C07D20090101
-
公开(公告)号:EA007155B1
公开(公告)日:2006-08-25
申请号:EA200500212
申请日:2003-07-16
Applicant: CELLTECH R&D LTD
Inventor: SKEAD BENJAMIN MARK , TYRRELL NICHOLAS DAVID , JONES STEPHEN WILFRED , BROOKES MICHAEL HANDFORTH
IPC: C07C227/18 , C07B61/00 , C07C229/36 , C07C231/02 , C07C303/38 , C07D213/81 , C07D311/96 , C07D471/04
Abstract: Способполученияклассаенамидныхпроизводныхфенилаланина, описанныхформулой (1), вкоторой Arпредставляетсобойнеобязательнозамещеннуюароматическуюилигетероароматическуюгруппу; Lпредставляетсобойсвязующуюгруппу, выбраннуюиз -N(R) [где Rявляетсяатомомводородаилинеобязательнозамещеннойнормальнойилиразветвленной C-алкильнойгруппой], -CON(R) или S(О)N(R)-; Rпредставляетсобойкарбоновуюкислоту (-СОН) илиеепроизводноеилибиостер; Rпредставляетсобойатомводородаили C-алкильнуюгруппу; R, Rи R, которыемогутбытьодинаковымиилиразными, представляютсобойатомилигруппу L(Alk)(R); иегосоли, сольваты, гидратыи N-оксиды; которыйвключаетвзаимодействиесоединенияформулы (2), где Qпредставляетсобойгруппу -N(R)H; иегосоли, сольваты, гидратыи N-оксиды; ссоединением ArW, вкотором W представляетсобойгруппу, выбраннуюиз X(причем Xявляетсяудаляемыматомомилигруппой), -СОХ(причем XявляетсяатомомгалогенаилиОН-группой) или -SOX(вкоторой Xявляетсяатомомгалогена).
-
公开(公告)号:DE60024854T2
公开(公告)日:2006-08-24
申请号:DE60024854
申请日:2000-10-19
Applicant: CELLTECH R&D LTD
Inventor: DAVIS MARTIN , MOFFAT FESTUS
IPC: C07D239/42 , A61K31/505 , A61P9/00 , A61P9/10 , A61P9/14 , A61P17/06 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D401/12 , C07D403/12 , C07D521/00
Abstract: Pyrimidines of formla (1) are described: wherein R 1 is a -XR 6 group; R 2 and R 3 which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, -OH, -OR 10 [where R 10 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group) -SH, -NO 2 , -CN, -SR 10 , -COR 10 , S(O)R 10 , -SO 2 R 8 , -SO 2 N(R 8 )(R 9 ), -CO 2 R 8 , -CON(R 8 )(R 9 ), -CSN(R 8 )(R 9 ), -NH 2 or substituted amino group; R 4 is a X 1 R 11 group where X 1 is a covalent bond or a -C(R 12 )(R 13 )- [where each of R 12 and R 13 is a hydrogen or halogen atom or a hydroxyl, alkyl or haloalkyl group] or -C(O)- group and R 11 is an optionally substituted phenyl, thienyl, thiazolyl or indolyl group; R 5 is a halogen atom or an alkynyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis
-
公开(公告)号:IL173474D0
公开(公告)日:2006-06-11
申请号:IL17347406
申请日:2006-01-31
Applicant: UCB PHARMA SA , UCB SA , CELLTECH R&D LTD
IPC: C12N20100101 , C12N1/20 , C12N1/21 , C12P21/02
Abstract: The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E. coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an inducible system, which method comprises: a) providing an E. coli host cell culture b) changing the growth rate of the E. coli host cells c) inducing expression of the recombinant protein wherein steps (b) and (c) can be performed in any order or simultaneously; and subsequently d) determining the yield of recombinant protein in the culture supernatant and the E. coli host cell periplasm e) comparing the yield determined in step (d) with the yield determined when at least one other growth rate has been used in step (b) f) selecting a growth rate from the comparison made in step (e) in which the partitioning of the recombinant protein between the supernatant and the periplasm is most suited to the primary recovery of the recombinant protein.
-
公开(公告)号:DE60209354D1
公开(公告)日:2006-04-27
申请号:DE60209354
申请日:2002-08-07
Applicant: CELLTECH R&D LTD
Inventor: DYKE JOAN , WATSON JOHN
IPC: C07D309/08 , A61K31/445 , A61K31/453 , A61P1/00 , A61P1/02 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D405/12
Abstract: Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.
-
公开(公告)号:NO20061576A
公开(公告)日:2006-04-07
申请号:NO20061576
申请日:2006-04-07
Applicant: CELLTECH R&D LTD
Inventor: SEHDEV MUKESH , REEKS DOMINIC GAMBIER , GLOVER DAVID JOHN
-
公开(公告)号:NZ532713A
公开(公告)日:2005-10-28
申请号:NZ53271302
申请日:2002-10-16
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04
Abstract: Disclosed are compounds of formula (Ia), wherein: A is -C(Rb)= or -C(Rb)(Rc)-, Ra, Rb and Rc are independently H or optionally substituted alkyl, X is O or S, Y is N, CH or substituted C, n is 0 or 1, Alk1 is an optionally substituted aliphatic or heteroaliphatic chain, L1 is a bond, or linker atom or group, Cy1 is H, or optionally substituted cycloaliphatic, polycycloaliphati, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic, Ar is an optionally substituted aromatic or heteroaromatic. The compounds are used in the manufacture of medicaments for the treatment of immune and inflammatory diseases.
-
139.
公开(公告)号:NZ528134A
公开(公告)日:2005-09-30
申请号:NZ52813402
申请日:2002-01-18
Applicant: CELLTECH R&D LTD
Inventor: BAILEY STUART , BROWN JULIEN ALISTAIR , BRAND STEPHEN , JOHNSON JAMES ANDREW , PORTER JOHN ROBERT , HEAD JOHN CLIFFORD
IPC: A61K31/198 , A61K31/4375 , A61K31/44 , A61K31/4406 , A61K31/497 , A61P3/10 , A61P9/00 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/00 , A61P37/06 , A61P43/00 , C07C229/34 , C07C229/46 , C07C233/82 , C07C321/22 , C07C323/30 , C07D213/81 , C07D213/89 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07C229/36
Abstract: Phenylalanine enamide derivatives of formula (I) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain -CH2-CH(R)-, -CH=C(R)- or -CH(CH2R)- X is an -N(R2) group; V is an oxygen (O) or sulphur (S) atom; RX and RY are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and RZ represents a halogen atom, or, -L1(Alk1)n(R3)v in which L is a covalent bond or a linker atom or group, Alk1 is an optionally substituted aliphatic or heteroaliphatic chain, R3 is a hydrogen or halogen atom or group selected from -OR3a [where R3a is a hydrogen atom or an optionally substituted alkyl or cycloalkyl], SR3a, -CN or an optionally substituted cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaIiphatic, aromatic or heteroaromatic group, n is zero or the integer 1 and v is the integer 1, 2 or 3 provided that when n is zero and L is a covalent bond v is the integer 1; and the salts, solvates, hydrates and N-oxides thereof. Furthermore compounds of formula (I) are able to inhibit the binding of integrins to their ligands and described is the use of compounds of formula (I) for the manufacture of a medicament for the treatment and/or prevention of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
-
公开(公告)号:DE69730345T2
公开(公告)日:2005-09-22
申请号:DE69730345
申请日:1997-12-03
Applicant: CELLTECH R&D LTD
Inventor: WARRELLOW GRAHAM JOHN , BROWN JULIEN ALISTAIR
IPC: A61K31/4409 , A61P1/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/06 , A61P37/08 , A61P43/00 , C07D213/38 , C07D213/53 , C07D213/89 , A61K31/44
-
-
-
-
-
-
-
-
-